
    
      This is a randomized, double-blind, placebo-controlled, parallel group, multiple dose,
      multicenter study with 5 treatment arms and 1 placebo arm. Patients should be treated with
      both metformin and SU or metformin alone. Patients will be randomized to 100,100 + 100, 200,
      200 + 200, and 400 mg/day or placebo, as an add-on to their current treatment. The study
      consists of 2 periods:

        -  A 14-day screening period for ascertaining the inclusion/exclusion criteria; and,

        -  A 13-week treatment period with different doses of BGP-15 or placebo as an add-on
           therapy to metformin and SU treatment or metformin treatment alone.
    
  